首页> Haematologica> Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.

Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.

导出 OA

翻译打印收藏纠错

第一作者： Chiara,Tarantelli

第一单位： Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona. chiara.tarantelli@ior.usi.ch.

作者： Chiara,Tarantelli ^[1] ; David,Wald ^[2] ; Nicolas,Munz ^[3] ; Filippo,Spriano ^[3] ; Alessio,Bruscaggin ^[3] ; Eleonora,Cannas ^[3] ; Luciano,Cascione ^[4] ; Eugenio,Gaudio ^[3] ; Alberto J,Arribas ^[4] ; Shivaprasad,Manjappa ^[5] ; Gaetanina,Golino ^[3] ; Lorenzo,Scalise ^[3] ; Maria Teresa,Cacciapuoti ^[6] ; Emanuele,Zucca ^[7] ; Anastasios,Stathis ^[8] ; Giorgio,Inghirami ^[6] ; Patrick H,Van Berkel ^[9] ; Davide,Rossi ^[7] ; Paolo F,Caimi ^[10] ; Francesca,Zammarchi ^[9] ; Francesco,Bertoni ^[11]

作者单位： Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona. chiara.tarantelli@ior.usi.ch. ^[1] Case Western Reserve University, Cleveland, OH. ^[2] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona. ^[3] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne. ^[4] Fred Hutchinson Cancer Center, Seattle, Washington. ^[5] Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY. ^[6] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona. ^[7] Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biomedical Sciences, USI, Lugano. ^[8] ADC Therapeutics (UK) Ltd., London. ^[9] Cleveland Clinic/Case Comprehensive Cancer Center, Cleveland, OH. ^[10] Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona. francesco.bertoni@ior.usi.ch. ^[11]